<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB05019</drugbank-id>
  <name>LC16M8</name>
  <description>LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.     </description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3166</ref-id>
        <pubmed-id>17052815</pubmed-id>
        <citation>Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M: LC16m8: an attenuated smallpox vaccine. Vaccine. 2006 Nov 17;24(47-48):7009-22. Epub 2006 Apr 21.</citation>
      </article>
      <article>
        <ref-id>A3167</ref-id>
        <pubmed-id>16698998</pubmed-id>
        <citation>Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa H, Ogata M, Fukushi S, Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S: LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol. 2006 Jun;80(11):5179-88.</citation>
      </article>
      <article>
        <ref-id>A3168</ref-id>
        <pubmed-id>16140764</pubmed-id>
        <citation>Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A: An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol. 2005 Sep;79(18):11873-91.</citation>
      </article>
      <article>
        <ref-id>A3169</ref-id>
        <pubmed-id>15753319</pubmed-id>
        <citation>Kidokoro M, Tashiro M, Shida H: Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. Epub 2005 Mar 7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in viral infection.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>LC16m8 is produced in cell culture from vaccinia&#13;
virus that has been attenuated, or modified, so that it can initiate an immune response without causing serious adverse side effects.       &#13;
&#13;
</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347909894</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>